MedTrace Logo

Use Lay Language. CAA-ri : a Series of 28 Patients

NCT03187886 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2017-12-05

No results posted yet for this study

Summary

INTRODUCTION: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a very rare manifestation of cerebral amyloid angiopathy, characterized by acute/subacute neurological deterioration and T2/FLAIR corticosubcortical or deep white matter hyperintensity. With the advent of new diagnostic criteria, there are more and more case reports and series reported; nevertheless, MRI findings and follow-up data need to be thoroughly described.

OBJECTIVES: Our aim in this multicentrical and retrospective study was to describe the clinical and radiological features of patients with CAA-ri and assess long-term prognosis.

METHODS: We reviewed the characteristics of 28 patients with CAA-ri including clinical data, systematic MRI analysis, cerebrospinal fluid results (including Alzheimer's disease biomarkers) and APOE genotype.

HYPOTHESIS: We aimed at describing the clinical and radiological characteristics of a cohort of patients with CAA-ri.

Conditions

  • Cerebral Amyloid Angiopathy Related Inflammation

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    collaborator OTHER

  • University Hospital, Toulouse

    collaborator OTHER

  • Centre hospitalier de Perpignan

    collaborator OTHER

  • Beziers Hospital

    collaborator OTHER

  • Narbonne Hospital

    collaborator OTHER

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Xavier AYRIGNAC, MD · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2017-06-12
Completion
2017-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03187886 on ClinicalTrials.gov